We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
The second stage in the evaluation of the dietary method change in the National Diet and Nutrition Survey (NDNS) rolling programme.
The first stage in the evaluation of the dietary method change in the National Diet and Nutrition Survey (NDNS) rolling programme.
An evaluation of the impact of the NHS Weight Loss Plan app to support weight management and health behaviours.
The third stage in the evaluation of the dietary method change in the National Diet and Nutrition Survey (NDNS).
Guidance on the safe and effective use of GLP-1 medicines for weight loss and diabetes.
The impact of COVID-19 on children, young people and adults living with obesity, tier 2 and 3 weight management provision and next steps for recovery.
GLP-1 medicines are licensed for Type 2 diabetes and weight management, and include the branded products Ozempic, Mounjaro and Wegovy
Do not include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab and requires JavaScript).